ROHTO PHARMACEUTICAL CO., LTD.
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- Public
- Established
- 1899-02-22
- Employees
- 7.2K
- Market Cap
- $5.4B
- Website
- http://www.rohto.co.jp
A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)
Phase 2
Completed
- Conditions
- SARS-CoV-2 Infection( COVID-19 )
- Interventions
- Biological: Mesenchymal stem cellBiological: Placebo
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT04888949
- Locations
- π―π΅
Osaka University Hospital, Suita, Osaka, Japan
A Study to Investigate the Safety and Efficacy of UC-MSCs in Pediatric Patients With Cerebral Palsy
Phase 1
Active, not recruiting
- Conditions
- Cerebral PalsyPeriventricular Leukomalacia
- Interventions
- Biological: UDI-001
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT04873752
- Locations
- π―π΅
Osaka City University Hospital, Osaka, Japan
An Exploratory Study of ADR-001 in Patients with Severe Pneumonia Caused by SARS-CoV-2 Infection
Phase 1
Completed
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2
- Interventions
- Biological: Mesenchymal stem cell
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT04522986
- Locations
- π―π΅
Osaka University Hospital, Suita, Osaka, Japan
An Follow-Up Study of Liver Cirrhosis
Completed
- Conditions
- Decompensated Liver Cirrhosis
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT03472742
- Locations
- π―π΅
Niigata University Medical & Dental Hospital, Niigata, Japan
A Study of ADR-001 in Patients With Liver Cirrhosis
Phase 1
Completed
- Conditions
- Decompensated Liver Cirrhosis
- Interventions
- Biological: Mesenchymal stem cell
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT03254758
- Locations
- π―π΅
Niigata University Medical & Dental Hospital, Niigata, Japan
π―π΅Nihon University Itabashi Hospital, Tokyo, Japan
Β© Copyright 2025. All Rights Reserved by MedPath